EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles



Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles



Fertility & Sterility 72(5): 823-829



Objective: To investigate the efficacy and safety of intravaginal Crinone 8% (Columbia Research Laboratories, Miami, FL) versus IM progesterone for luteal phase support after IVF-ET. Design: Prospective open trial with comparison to historical controls. Setting: University hospital. Patient(s): Two hundred six women undergoing IVF-ET. Intervention(s): One hundred patients received Crinone vaginal progesterone gel (90 mg once daily) and 106 patients received IM progesterone (50 mg once daily) beginning on the evening of oocyte retrieval. Main Outcome Measure(s): Pregnancy and miscarriage rates, and midluteal serum progesterone levels. Result(s): Positive beta-hCG pregnancy rates, clinical pregnancy rates per transfer, and ongoing pregnancy rates were similar for the Crinone and IM progesterone groups. Women who received Crinone had higher rates of biochemical pregnancy loss but lower rates of clinical pregnancy loss (i.e., spontaneous abortion) than women who received IM progesterone. Midluteal serum progesterone concentrations were significantly higher in the IM progesterone group (94.3 +- 8.8 ng/mL versus 57.7 +- 7.4 ng/mL). Several women who received Crinone had vaginal bleeding 11-13 days after oocyte retrieval. Conclusion(s): For all age categories, positive beta-hCG and ongoing pregnancy rates were similar when Crinone or IM progesterone was given for luteal phase support in IVF-ET cycles, despite lower serum progesterone concentrations and higher rates of biochemical pregnancy loss with Crinone. Although the results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study.

(PDF emailed within 0-6 h: $19.90)

Accession: 011619197

Download citation: RISBibTeXText

PMID: 10560985

DOI: 10.1016/s0015-0282(99)00362-3



Related references

Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertility and Sterility 94(7): 2596-2599, 2011

Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction 11(10): 2085-2089, 1996

Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone--impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility 95(2): 617-620, 2011

Luteal support after in-vitro fertilization: Crinone 8 percent, a sustained release vaginal progesterone gel, versus utrogestan, an oral micronized progesterone. Human Reproduction (Oxford) 11(10): 2085-2089, 1996

Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertility and Sterility 97(2): 344-348, 2012

Intramuscular vs vaginal progesterone for luteal support in cycles of in vitro fertilization. Ginekologia Polska 71(9): 1064-1070, 2000

Intramascular versus vaginal progesterone for luteal support in cycles of in-vitro fertilization. Human Reproduction (Oxford) 14(ABSTR BOOK 1): 363, June, 1999

Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective randomized study. Minerva Ginecologica 53(4): 297-301, 2001

Comparison of Crinone 8% intravaginal gel and intramuscular progesterone for luteal support in in vitro fertilization. Journal of the Chinese Medical Association 71(8): 381-385, 2008

Efficacy and tolerability of vaginal progesterone capsules (Utrogest (TM) 200) compared with progesterone gel (Crinone (TM) 8%) for luteal phase support during assisted reproduction. Fertility and Sterility 83(6): 1641-1649, 2005

Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility 83(6): 1641-1649, 2005

A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction 27(12): 3467-3473, 2013

Disturbances of the endometrium in the luteal phase of cycles stimulated for in vitro fertilization and of normal cycles treated with vaginal progesterone. Annales Chirurgiae et Gynaecologiae. Supplementum 208: 33-39, 1994